ImmunityBio (NASDAQ:IBRX) Trading 41.9% Higher – What’s Next?

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price rose 41.9% on Wednesday . The company traded as high as $8.68 and last traded at $8.54. Approximately 79,194,862 shares changed hands during mid-day trading, an increase of 87% from the average daily volume of 42,421,027 shares. The stock had previously closed at $6.02.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European Commission authorization expands ImmunityBio’s commercial footprint across four regulatory jurisdictions quickly, including key markets and additional indications for Anktiva — a major growth catalyst for sales and addressable market. What’s Behind The Jump In ImmunityBio Stock?
• Positive Sentiment: Productive regulatory discussions and a Saudi filing/“nod” for bladder cancer (BCG-related) advance market access in Saudi Arabia — investors view this as near-term revenue upside and validation in a large, well-funded market. ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority
• Positive Sentiment: Market coverage and pre-market headlines highlighted the Saudi BCG update and growing retail interest, amplifying buying momentum. Analyst support (D. Boral Capital reaffirmed buy with a $24 PT) provides a bullish price-target narrative. How high can IBRX stock go now?
• Neutral Sentiment: Commercial performance context: Seeking Alpha notes Anktiva’s strong early commercial traction (FY25 revenue cited) and upcoming pivotal trial readouts (bladder cancer, glioblastoma) — these are major potential upside catalysts but also make valuation sensitive to trial setbacks. ImmunityBio: The Story Surrounding Anktiva So Far
• Neutral Sentiment: Reported short-interest data is anomalous/unclear (entries show zero shares / NaN); with very high trading volume, short-interest metrics may not reflect real positioning — monitor updated, reliable short-interest reports for true bearish pressure. Short Interest Data (company reports)
• Negative Sentiment: Pomerantz law firm announced an investigation on behalf of ImmunityBio investors — potential litigation or disclosure risk that could create headline-driven volatility and act as a near-term overhang. Pomerantz Law Firm Investigates Claims

Analysts Set New Price Targets

IBRX has been the subject of several analyst reports. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Jefferies Financial Group increased their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Piper Sandler raised their price target on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of ImmunityBio in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $11.80.

ImmunityBio Stock Up 41.9%

The company has a 50 day simple moving average of $4.10 and a 200 day simple moving average of $2.99. The company has a market capitalization of $8.41 billion, a price-to-earnings ratio of -20.83 and a beta of 0.16.

Insider Buying and Selling

In other news, Director Barry J. Simon sold 151,967 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the transaction, the director owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. This trade represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 226,967 shares of company stock valued at $1,531,912. Corporate insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in shares of ImmunityBio by 193.4% during the first quarter. AQR Capital Management LLC now owns 44,448 shares of the company’s stock worth $134,000 after purchasing an additional 29,297 shares in the last quarter. CWM LLC raised its holdings in shares of ImmunityBio by 849.2% during the 2nd quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after buying an additional 43,583 shares during the period. RFG Advisory LLC acquired a new position in ImmunityBio during the 2nd quarter worth approximately $103,000. Chicago Partners Investment Group LLC purchased a new position in ImmunityBio in the 2nd quarter worth approximately $70,000. Finally, Dillon & Associates Inc. acquired a new stake in ImmunityBio in the second quarter valued at approximately $68,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.